Kolexia
Damier Philippe Neurologie
Damier Philippe
Neurologie
Hôpital Laennec
Saint-Herblain, France
172 Activités
174 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Parkinson Dyskinésies Dystonie Troubles de la motricité Maladie de Huntington Maladies neurodégénératives Tremblement Démence Dysarthrie

Collaborateurs

Voir plus
Derkinderen Pascal
Derkinderen Pascal
Hôpital Laennec, Saint-Herblain, France
Vidailhet Marie-Jose
Vidailhet Marie-Jose
Hôpital Pitie Salpetriere, Paris, France
Rascol Olivier
Rascol Olivier
Labo Pharmacol Med Et Clinique, Toulouse, France
Tison Francois
Tison Francois
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Abbvie
4 collaboration(s)
Dernière en 2023
B3TSI
4 collaboration(s)
Dernière en 2021
Roche
4 collaboration(s)
Dernière en 2022
Merck-Serono
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
LUMA: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
Essai Clinique (Biogen)   15 mars 2024
ACTIVATE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Essai Clinique (Bial R&D Investments, S.A.)   13 mars 2024
Rare Missense Variants in KCNJ10 Are Associated with Paroxysmal Kinesigenic Dyskinesia.
Movement disorders : official journal of the Movement Disorder Society   04 mars 2024
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Movement disorders : official journal of the Movement Disorder Society   30 janvier 2024
Lessons from multitarget neurostimulation in isolated dystonia: Less is more?
Brain stimulation   03 janvier 2024
TEMPO-2: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)
Essai Clinique (Cerevel Therapeutics, LLC)   28 novembre 2023
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease: A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease
Essai Clinique (Il-Yang Pharm. Co., Ltd.)   26 septembre 2023
Response to: increased prevalence of normal pressure hydrocephalus in both variants of frontotemporal dementia: a 10-year retrospective study.
Brain communications   15 septembre 2023
Nicotine in Parkinson's Disease - a Therapeutic Track Gone up in Smoke?
NEJM evidence   22 août 2023
Correction: Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome.
Tremor and other hyperkinetic movements (New York, N.Y.)   14 juillet 2023